Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LGS DISCOVER Study
NCT05219617Phase 3Recruiting
- Sponsor
- SK Life Science, Inc.
- Start
- Apr 2022
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of carisbamate in Lennox-Gastaut syndrome (LGS) (4 arms), sponsored by SK Life Science, Inc. Primary endpoint: Percentage change from baseline in the total frequency of countable drop seizures at 14 weeks. Started Apr 2022; status: recruiting.
02
Drugs
carisbamate
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT05219617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05219617.